JGK-263

• Description :

  JGK-263 is an orally active Glycogen synthase kinase-3β (GSK-3β) inhibitor. JGK-263 exhibits neuroprotective effect and can improve motor function. JGK-263 can be used for the research of neurological disease, such as amyotrophic lateral sclerosis (ALS) [1].

• UNSPSC :

  12352005

• Target :

  GSK-3

• Related Pathways :

  PI3K/Akt/mTOR; Stem Cell/Wnt

• Field of Research :

  Neurological Disease

• Smiles :

  O=C1NN=C2C(NCCCC3=CC=NC=C3)=CC(Cl)=CN21

• Molecular Formula :

  C14H14ClN5O

• Molecular Weight :

  303.75

• References & Citations :

  [1]Ahn SW, et al. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis. J Neurol Sci. 2014 May 15;340 (1-2) :112-6.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  GSK-3β

• CAS Number :

  [1408054-46-5]